StevenDavidGoreMD

Oncology • Rockville, MD

Hematologic Oncology

Professor, Medicine (Hematology), Yale School of Medicine

Join to view full profile

Dr. Gore is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Gore's full profile

Already have an account?

Office
9609 Medical Center Drive
Rockville, MD 20850
Phone+1 443-854-1650
Is this information wrong?

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1987 - 1990
University of ChicagoResidency, Internal Medicine, 1984 - 1987
Yale School of MedicineClass of 1984

Certifications & Licensure

MD State Medical License 1987 - 2024
CT State Medical License 2013 - 2020
IL State Medical License 1985 - 1987
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Super Doctor SuperDoctors.com

Clinical Trials

Azacitidine Plus Phenylbutyrate in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Start of enrollment: 2000 May 01
Completed
Phase 1
Phenylbutyrate and Tretinoin in Treating Patients With Hematologic Cancer Start of enrollment: 2000 Dec 01
Completed
Phase 1
Combination Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia Start of enrollment: 2004 Oct 01
Completed
Phase 2
Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Start of enrollment: 2006 Aug 01
Completed
Phase 2
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia Start of enrollment: 2009 Jan 29
Active, not recruiting
Phase 3
Trial of High Dose Lenalidomide in Patients With MDS and AML With Trilineage Dysplasia Start of enrollment: 2009 Jul 01
Terminated
Phase 2
Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Start of enrollment: 2012 Dec 14
Completed
Phase 1
Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2013 Dec 09
Active, not recruiting
Phase 3
Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA Start of enrollment: 2013 Dec 01
Completed
Phase 2
Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia Start of enrollment: 2014 May 19
Active, not recruiting
Phase 3
Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2011 Feb 04
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or ...
Jan Philipp Bewersdorf, Rory M Shallis, Elad Sharon, Silvia Park, Rahul Ramaswamy, Caroline E Roe, Jonathan M Irish, Anne Caldwell, Wei Wei, Abdulraheem Yacoub, Yazan ...> ;Annals of Hematology. 2024 Jan 1
4 citations
Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Cons...
Maximilian Stahl, Jan Philipp Bewersdorf, Zhuoer Xie, Matteo Giovanni Della Porta, Rami Komrokji, Mina L Xu, Omar Abdel-Wahab, Justin Taylor, David P Steensma, Daniel ...> ;Blood Reviews. 2023 Nov 1
2 citations
Berzosertib Plus Topotecan vs Topotecan Alone in Patients With Relapsed Small Cell Lung Cancer: A Randomized Clinical Trial.
Nobuyuki Takahashi, Zhonglin Hao, Liza C Villaruz, Jun Zhang, Jimmy Ruiz, W Jeffrey Petty, Hirva Mamdani, Jonathan W Riess, Jorge Nieva, Jose M Pachecho, Alexander D F...> ;JAMA Oncology. 2023 Dec 1
1 citations
Vemurafenib and Obinutuzumab as Frontline Therapy for Hairy Cell Leukemia.
Devlin, S., von Keudell, G., Vemuri, S., Shukla, M., Falco, V., Cuello, B., Park, J., Durham, B., Winer, E., Huntington, S., Gore, S., Stone, R., Abdel-Wahab, O., Tall...> ;NEJM Evidence. 2023 Oct 1
2 citations
Statin use, survival and incidence of thrombosis among older patients with polycythemia vera and essential thrombocythemia.
Nikolai A Podoltsev, Rong Wang, Rory M Shallis, Jessica M Stempel, Mengyang Di, Natalia Neparidze, Amer M Zeidan, Scott F Huntington, Smith Giri, Sarah C Hull, Steven ...> ;Cancer Medicine. 2023 Sep 1
Discordant pathologic diagnoses of myelodysplastic neoplasms and their implications for registries and therapies.
Edward J Gorak, Michael Otterstatter, Tareq Al Baghdadi, Nancy Gillis, James M Foran, Jane Jijun Liu, Rafael Bejar, Steven D Gore, Steven H Kroft, Alexandra Harrington...> ;Blood Advances. 2023 Oct 24
3 citations
Health-related quality of life and vulnerability among people with myelodysplastic syndromes: a US national study.
Gregory A Abel, Donnie Hebert, Cecilia Lee, Dana Rollison, Nancy Gillis, Rami Komrokji, James M Foran, Jane Jijun Liu, Tareq Al Baghdadi, Joachim Deeg, Steven Gore, Wa...> ;Blood Advances. 2023 Jul 25
3 citations
Utility of targeted gene sequencing to differentiate myeloid malignancies from other cytopenic conditions.
Amy E DeZern, Johannes B Goll, R Coleman Lindsley, Rafael Bejar, Steffanie H Wilson, Donnie Hebert, Joachim Deeg, Ling Zhang, Steven Gore, Tareq Al Baghdadi, Jaroslaw ...> ;Blood Advances. 2023 Jul 25
6 citations
Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1International Workshop on MDS (iwMDS) Of t...
Jan Philipp Bewersdorf, Zhuoer Xie, Rafael Bejar, Uma Borate, Jacqueline Boultwood, Andrew M Brunner, Rena Buckstein, Hetty E Carraway, Jane E Churpek, Naval G Daver, ...> ;Blood Reviews. 2023 Jul 1
Expanding access to early phase trials: the CATCH-UP.2020 experience.
Joaquina C Baranda, Francisco J Diaz, Larry Rubinstein, Anthony F Shields, Farshid Dayyani, Amitkumar Mehta, Janice M Mehnert, Jonathan Trent, Rodwell Mabaera, Margare...> ;JNCI Cancer Spectrum. 2023 Jan 3
Quantitation of the ataxia-telangiectasia-mutated and Rad3-related inhibitor elimusertib (BAY-1895344) in human plasma using LC-MS/MS.
Brian F Kiesel, Robert A Parise, Anuradha Krishnamurthy, Steven Gore, Jan H Beumer> ;Biomedical Chromatography. 2022 Nov 1
4 citations
An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS.
Maximilian Stahl, Omar Abdel-Wahab, Andrew H Wei, Michael R Savona, Mina L Xu, Zhuoer Xie, Justin Taylor, Daniel Starczynowski, Guillermo F Sanz, David A Sallman, Vale...> ;Blood Advances. 2023 Jun 27
2 citations
Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea.
Rong Wang, Rory M Shallis, Jessica M Stempel, Scott F Huntington, Amer M Zeidan, Steven D Gore, Xiaomei Ma, Nikolai A Podoltsev> ;Blood Advances. 2023 Mar 14
2 citations
Agent Orange and dioxin-induced myeloid leukemia: a weaponized vehicle of leukemogenesis.
Rory M Shallis, Steven D Gore> ;Leukemia & Lymphoma. 2022 Jul 1
Validation of a robust and rapid liquid chromatography tandem mass spectrometric method for the quantitative analysis of navitoclax.
Susan C Scott, Nicole M Anders, Ping He, Avelina Hemingway, Steven D Gore, Christine L Hann, Michelle A Rudek> ;Biomedical Chromatography. 2022 Jun 1
1 citations
Validation of a robust and rapid liquid chromatography tandem mass spectrometric method for the quantitative analysis of navitoclax
Susan C. Scott, Nicole M. Anders, Ping He, Avelina Hemingway, Steven D. Gore, Christine L. Hann, Michelle A. Rudek> ;Biomedical Chromatography. 2021 Nov 30
5 citations
Molecular testing of isolated myeloid sarcoma allows successful FLT3-targeted therapy.
Rory M. Shallis, Darko Pucar, Sudhir Perincheri, Steven D. Gore, Stuart Seropian, Nikolai A. Podoltsev, Amer M. Zeidan> ;Annals of Hematology. 2021 Oct 22
33 citations
Haploidentical vs. sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia.
Matthew J Wieduwilt, Leland Metheny, Mei-Jie Zhang, Hai-Lin Wang, Noel Estrada-Merly, David I. Marks, A Samar Al-Homsi, Lori Muffly, Nelson J. Chao, David A. Rizzieri,...> ;Blood Advances. 2021 Sep 21
17 citations
How to Provide the Needed Protection from COVID-19 to Patients with Hematologic Malignancies.
Antoni Ribas, Katie M. Campbell, Faith E. Davies, Steven D. Gore, Ronald Levy, Lee M. Greenberger> ;Blood Cancer Discovery. 2021 Sep 15
5 citations
Phase 1 study of the histone deacetylase inhibitor entinostat plus clofarabine for poor-risk Philadelphia chromosome-negative (newly diagnosed older adults or adults w...
Hetty E. Carraway, Yazeed Sawalha, Ivana Gojo, Min-Jung Lee, Sunmin Lee, Yusuke Tomita, Akira Yuno, Jackie Greer, B. Douglas Smith, Keith W. Pratz, Mark J. Levis, Stev...> ;Leukemia Research. 2021 Sep 10
Clinical effectiveness of DNA methyltransferase inhibitors and lenalidomide in older patients with refractory anemia with ring sideroblasts: a population-based study i...
Xiaoyi Wang, Amer M. Zeidan, Rong Wang, Jan Philipp Bewersdorf, Chi Zhang, Nikolai A. Podoltsev, Scott F. Huntington, Steven D. Gore, Xiaomei Ma> ;Leukemia & Lymphoma. 2021 Apr 24
1 citations
Challenges in the Evaluation and Management of Toxicities Arising From Immune Checkpoint Inhibitor Therapy for Patients With Myeloid Malignancies.
Rory M. Shallis, Jan Philipp Bewersdorf, David M Swoboda, Wei Wei, Lohith Gowda, Thomas Prebet, Stephanie Halene, Manoj M. Pillai, Terri L. Parker, Natalia Neparidze, ...> ;Clinical Lymphoma, Myeloma & Leukemia. 2021 Jan 12
4 citations
High dose cyclophosphamide for cytoreduction in patients with acute myeloid leukemia with hyperleukocytosis or leukostasis.
Jennifer Zhao, Jan Philipp Bewersdorf, Sara Mohamed Jaszczur, Andrew Kowalski, Sarah Perreault, Molly Schiffer, Steven D. Gore, Nikolai A. Podoltsev, Thomas Prebet, Ro...> ;Leukemia & Lymphoma. 2021 Apr 16
57 citations
Myeloid sarcoma, chloroma, or extramedullary acute myeloid leukemia tumor: A tale of misnomers, controversy and the unresolved
Rory M. Shallis, Robert Peter Gale, Hillard M. Lazarus, Kenneth B. Roberts, Mina L. Xu, Stuart Seropian, Steven D. Gore, Nikolai A. Podoltsev> ;Blood Reviews. 2021 May 1
5 citations
The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia.
Michael Boyiadzis, Ivan Aksentijevich, Daniel A. Arber, John Barrett, Renier J. Brentjens, Jill Brufsky, Jorge E. Cortes, Marcos de Lima, Stephen J. Forman, Ephraim J....> ;Journal for Immunotherapy of Cancer. 2020 Oct 19
Join now to see all

Abstracts/Posters

Clonal Cytopenias of Undetermined Significance Are Common in Cytopenic Adults Evaluated for MDS in the National MDS Study
Steven D. Gore, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Incidence and Risk Factors of Second Malignancies Among Medicare Beneficiaries with Newly-Diagnosed Philadelphia Chromosome-Negative Classical Myeloproliferative Neopl...
Steven D. Gore, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Clinical Outcomes of Older Patients (pts) with Acute Myeloid Leukemia (AML) Receiving Hypomethylating Agents (HMAs): A Large Population-Based Study in the United State...
Steven D. Gore, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Clinical Effectiveness of Hypomethylating Agents (HMAs) and Lenalidomide (Len) in Older Patients (pts) with Refractory Anemia with Ring Sideroblasts: A Large Populatio...
Steven D. Gore, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
The Impact of the 2011 European Leukemianet (ELN) Guidelines for Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms on Therapeutic Phlebotomy and ...
Steven D. Gore, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Immune Checkpoint Inhibitor Therapy for Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes: A Single-Center Experience
Steven D. Gore, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
The VITAL Trial: Phase II Trial of Vosaroxin and Infusional Cytarabine for Frontline Treatment of acute Myeloid LeukemiaClinically Relevant Abstract
Steven D. Gore, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Patterns of Care and Clinical Outcomes with 7+3 Induction Chemotherapy for Patients (pts) with Acute Myeloid Leukemia (AML) in the United States (US): A Large Populati...
Steven D. Gore, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all

Lectures

Wide Variation in Use and Interpretation of Gene Mutation Profiling Panels Among Health Care Providers of Patients with Myelodysplastic Syndromes (MDS): Results of a L...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Impact of Leukapheresis and Time to Chemotherapy on Outcomes of Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Presenting with Hyperleukocytosis: An ...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Riding the Wave: Clinical Management of Myeloid Malignancies in an Era of Novel Therapies
60th American Society of Hematology Annual Meeting - 11/30/2018

Press Mentions

Dioxin Exposure from Agent Orange Linked to AML and MDSApril 1st, 2022
Yale Cancer Center Investigators Show Recommended, but Underused Treatment for Rare Blood Cancer Saves LivesNovember 5th, 2018
$Alternative Option to Intensive Chemotherapy for Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)$
Alternative Option to Intensive Chemotherapy for Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)December 6th, 2016
Join now to see all

Grant Support

Targeting Epigenomics In Myeloid NeoplasmsNational Cancer Institute2005–2011
Mechanism Of Combined 'Epigenetic Therapy'In Myeloid MalignanciesNational Cancer Institute2007–2009
Arsenic Trioxide In Primary Curative APL TherapyNational Cancer Institute2004–2008
5-Azacytidine And MS-275 In Myeloid MalignanciesNational Cancer Institute2004–2005
DNA Methyltransferase/Histone Deacetylase InhibitionNational Cancer Institute2000–2002
Clinical Histone Deacetylase Inhibition And RetinoidsNational Cancer Institute2000–2001
Butyric Acid Derivatives In Myeloid MalignanciesNational Cancer Institute1995–1999
Phase I Trial Of Sodium Phenylbutyrate (EL532) In Myelodysplastic PatientsNational Center For Research Resources1997